Free Trial

Cardinal Health (CAH) Stock Forecast & Price Target

Cardinal Health logo
$118.27 +0.35 (+0.30%)
(As of 12/31/2024 05:32 PM ET)

Cardinal Health - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
5
Buy
8

Based on 13 Wall Street analysts who have issued ratings for Cardinal Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 5 have given a hold rating, and 8 have given a buy rating for CAH.

Consensus Price Target

$127.50
7.80% Upside
According to the 13 analysts' twelve-month price targets for Cardinal Health, the average price target is $127.50. The highest price target for CAH is $139.00, while the lowest price target for CAH is $107.00. The average price target represents a forecasted upside of 7.80% from the current price of $118.27.
Get the Latest News and Ratings for CAH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cardinal Health and its competitors.

Sign Up

CAH Analyst Ratings Over Time

TypeCurrent Forecast
1/3/24 to 1/2/25
1 Month Ago
12/4/23 to 12/3/24
3 Months Ago
10/5/23 to 10/4/24
1 Year Ago
1/3/23 to 1/3/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
4 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
4 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$127.50$123.00$119.36$99.23
Forecasted Upside7.80% Upside-0.19% Downside6.60% Upside-5.24% Downside
Consensus Rating
Moderate Buy
Hold
Moderate Buy
Hold

CAH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CAH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cardinal Health Stock vs. The Competition

TypeCardinal HealthMedical CompaniesS&P 500
Consensus Rating Score
2.62
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside7.80% Upside24,318.21% Upside14.94% Upside
News Sentiment Rating
Positive News

See Recent CAH News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/17/2024Morgan Stanley
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$127.00 ➝ $136.00+18.21%
12/13/2024Wells Fargo & Company
3 of 5 stars
S. Baxter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Equal Weight$101.00 ➝ $127.00+8.12%
12/4/2024Mizuho
2 of 5 stars
A. Hynes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold ➝ Outperform$139.00+12.79%
11/4/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$119.00 ➝ $124.00+9.48%
11/4/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$134.00 ➝ $139.00+21.30%
11/4/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$117.00 ➝ $133.00+14.53%
9/11/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$115.00 ➝ $125.00+10.34%
8/21/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$111.00 ➝ $123.00+12.23%
8/15/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$130.00 ➝ $137.00+28.81%
8/15/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetIn-Line ➝ In-Line$105.00 ➝ $115.00+8.12%
7/19/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$115.00 ➝ $107.00+11.98%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/26/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$125.00+15.64%
8/16/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$88.00 ➝ $90.00-0.56%
7/17/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$91.00 ➝ $99.00+6.29%
6/12/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$90.00 ➝ $100.00+15.82%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:50 AM ET.


Should I Buy Cardinal Health Stock? CAH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, December 22, 2024. Please send any questions or comments about these Cardinal Health pros and cons to contact@marketbeat.com.

Cardinal Health
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Cardinal Health, Inc.:

  • Cardinal Health, Inc. has recently received a price target increase from Argus, raising it from $115.00 to $125.00, indicating positive analyst sentiment and potential for stock appreciation.
  • The company reported strong quarterly earnings, with an EPS of $1.88, surpassing analysts' expectations of $1.62, showcasing its ability to generate profits effectively.
  • With a current stock price of approximately $117.46, Cardinal Health, Inc. is trading near its 50-day moving average of $117.00, suggesting stability in its recent performance.
  • Cardinal Health, Inc. has a consensus rating of "Moderate Buy" from analysts, with nine analysts recommending a buy, which reflects overall confidence in the company's future performance.
  • The company has a market capitalization of around $28.43 billion, indicating it is a significant player in the healthcare sector, which can provide investors with a sense of security in their investment.

Cardinal Health
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Cardinal Health, Inc. for these reasons:

  • Cardinal Health, Inc. has experienced a revenue decline of 4.3% compared to the same quarter last year, which may raise concerns about its growth trajectory.
  • The company has a negative return on equity of 56.56%, indicating that it is not effectively generating profits from its equity, which could be a red flag for potential investors.
  • Despite a recent dividend declaration, the company has cut its dividend, which may signal financial strain and could deter income-focused investors.
  • Cardinal Health, Inc. has a relatively low net margin of 0.56%, suggesting that it retains a small portion of its revenue as profit, which may limit its ability to reinvest in growth opportunities.
  • One investment analyst has rated the stock with a sell rating, which could indicate potential risks or concerns that investors should consider before investing.

CAH Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Cardinal Health is $127.50, with a high forecast of $139.00 and a low forecast of $107.00.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardinal Health in the last twelve months. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CAH shares.

According to analysts, Cardinal Health's stock has a predicted upside of 7.80% based on their 12-month stock forecasts.

Over the previous 90 days, Cardinal Health's stock had 1 upgrade by analysts.

Cardinal Health has been rated by research analysts at Barclays, Deutsche Bank Aktiengesellschaft, Mizuho, Morgan Stanley, UBS Group, and Wells Fargo & Company in the past 90 days.

Analysts like Cardinal Health less than other "medical" companies. The consensus rating score for Cardinal Health is 2.62 while the average consensus rating score for "medical" companies is 2.81. Learn more on how CAH compares to other companies.


This page (NYSE:CAH) was last updated on 1/2/2025 by MarketBeat.com Staff
From Our Partners